VivoSeq
Immunology

Macrophage Activation Syndrome

7

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Macrophage Activation Syndrome is an early-stage landscape with 7 programs across 6 companies. The most active players are Iovance Biotherapeutics, Inc., Amgen, Essen Biotech. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1E

Essen Biotech

1 program

Phase 2T

TJ Biopharma Co., Ltd.

1 program

Phase 3Incyte logo

Incyte

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Protein / enzyme229%
Monoclonal antibody114%

Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Unknown status2 · 33%
Terminated1 · 17%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Active, not recruiting·National Cancer Institute (NCI)·N/A·NCT03827343·500 enrolled
Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis
Completed·UUniversity Hospital, Rouen·N/A·NCT03721809·27 enrolled
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
Completed·TTJ Biopharma Co., Ltd.·Phase 2·NCT07034209·18 enrolled
Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
Terminated·UUniversity of Alabama at Birmingham·Phase 1·NCT02780583·9 enrolled
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
Unknown status·—·Phase 3·NCT05137496·40 enrolled
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）
Unknown status·PPeking University People's Hospital·Phase 1/2·NCT02569463·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)